Q-omics provides the consensus-scored KDM3B profile across patient tissues and cancer cell-line models. KDM3B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KDM3B is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, KDM3B protein abundance shows 32,300 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LIHC, and LSCC as cancer lineages where KDM3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KDM3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KDM3B survival associations across molecular data types. KDM3B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KDM3B RNA expression–survival associations across cancer types. High KDM3B expression shows unfavorable associations in HNSC and ESCA, but favorable associations in KIRC, READ, LGG and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KDM3B RNA expression.
This table summarizes KDM3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 8. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KDM3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KDM3B shows lower tumor expression in UCEC and KICH and higher tumor expression in LIHC, CHOL, STAD and READ. The LIHC box plot shows higher KDM3B RNA expression in tumor versus normal tissue (log2 FC = +1.400, t-test p < 0.001).
This table shows molecular features associated with KDM3B in patient tissues and cancer cell lines. In patient samples, KDM3B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KDM3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
